New blood test may spot hidden tumors in MEN1 patients
NCT ID NCT06430021
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a blood test for a protein called hPG80 can help find neuroendocrine tumors (NETs) earlier in people with MEN1, a genetic condition that raises tumor risk. About 297 participants with MEN1 will give blood samples, which will be compared to standard imaging tests. If hPG80 works well, it could offer a simpler, less stressful way to monitor for these tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEN1 MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chu Dijon Bourgogne
RECRUITINGDijon, 21000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?
- Experimental drug targets Hard-to-Treat neuroendocrine cancers
- New camera could make cancer treatment safer by better tracking radiation
- Radioactive drug targets hard-to-treat neuroendocrine tumors in early trial